150 related articles for article (PubMed ID: 20668965)
1. Aspirin intake may prevent metastasis in patients with triple-negative breast cancer.
Ararat E; Sahin I; Altundag K
Med Oncol; 2011 Dec; 28(4):1308-10. PubMed ID: 20668965
[No Abstract] [Full Text] [Related]
2. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).
Rakha EA; Ellis IO; Reis-Filho JS
Mod Pathol; 2008 Aug; 21(8):1060-1; author reply 1061-2. PubMed ID: 18654595
[No Abstract] [Full Text] [Related]
3. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.
Yi SY; Ahn JS; Uhm JE; Lim DH; Ji SH; Jun HJ; Kim KH; Chang MH; Park MJ; Cho EY; Choi YL; Park YH; Im YH
BMC Cancer; 2010 Oct; 10():527. PubMed ID: 20920367
[TBL] [Abstract][Full Text] [Related]
4. Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer.
Cicin I; Karagol H; Usta U; Sezer A; Uzunoglu S; Alas-Cosar R; Yetisyigit T; Uygun K
Med Oncol; 2009; 26(3):335-43. PubMed ID: 19003545
[TBL] [Abstract][Full Text] [Related]
5. [Expression of estrogen and progesterone receptors and HER-2 by breast cancer cells].
Zaĭrat'iants OV; Kolobov SV; Akopian IG; Opalenov KV; Barsanova TG
Arkh Patol; 2004; 66(5):9-12. PubMed ID: 15575377
[TBL] [Abstract][Full Text] [Related]
6. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
Bao G; Yang DQ; Zhou B; Liu P; Wang S; Cheng L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2843-5. PubMed ID: 18167290
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer in focus: treatment options for triple-negative metastatic breast cancer.
O'Shaughnessy JA
Clin Adv Hematol Oncol; 2012 Jan; 10(1):43-5. PubMed ID: 22398807
[No Abstract] [Full Text] [Related]
8. Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.
Anderson WF; Rosenberg PS; Katki HA
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777110
[No Abstract] [Full Text] [Related]
9. Association of aspirin use and hormone receptor status with breast cancer risk.
Woloshin S; Schwartz LM
JAMA; 2004 Sep; 292(12):1426-7; author reply 1427. PubMed ID: 15383505
[No Abstract] [Full Text] [Related]
10. Breast cancer molecular subtypes--modern therapeutic concepts for targeted therapy of a heterogeneous entity.
Liedtke C; Kiesel L
Maturitas; 2012 Dec; 73(4):288-94. PubMed ID: 23020990
[TBL] [Abstract][Full Text] [Related]
11. Changes of expression of estrogen and progestrone receptors, human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy in the treatment of breast cancer.
Li ML; Dong Y; Luan SL; Zhao ZH; Ning FL
J Biol Regul Homeost Agents; 2016; 30(4):1059-1065. PubMed ID: 28078854
[TBL] [Abstract][Full Text] [Related]
12. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
[TBL] [Abstract][Full Text] [Related]
13. Aspirin and breast cancer prevention: the estrogen connection.
DuBois RN
JAMA; 2004 May; 291(20):2488-9. PubMed ID: 15161901
[No Abstract] [Full Text] [Related]
14. Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor, progesterone receptor, and HER-2 protein expression in tumor samples of premenopausal breast cancer patients?
Alimonti A; Ferretti G; Cognetti F
J Clin Oncol; 2005 Dec; 23(34):8918; author reply 8918-9. PubMed ID: 16314657
[No Abstract] [Full Text] [Related]
15. A 10-year follow-up of triple-negative breast cancer patients in Taiwan.
Lin C; Chien SY; Kuo SJ; Chen LS; Chen ST; Lai HW; Chang TW; Chen DR
Jpn J Clin Oncol; 2012 Mar; 42(3):161-7. PubMed ID: 22287721
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer: novel therapies and new directions.
Pal SK; Mortimer J
Maturitas; 2009 Aug; 63(4):269-74. PubMed ID: 19632796
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine for breast cancer: it is a new day!
Russell CA
Am J Surg; 2014 Mar; 207(3):321-5. PubMed ID: 24581758
[TBL] [Abstract][Full Text] [Related]
18. Two birds with one stone: octreotide treatment for acromegaly and breast cancer.
Chae YK; Hu MI; Katz RL; Chavez-MacGregor M; Haluska P; Meric-Bernstam F; Gonzalez-Angulo AM; Melhem-Bertrandt A
J Clin Oncol; 2013 Aug; 31(23):e398-400. PubMed ID: 23796991
[No Abstract] [Full Text] [Related]
19. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
20. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
Desouki MM; Atta IS; Wolff DJ; Self SE
Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
